Aim To compare the predictive values of enzyme-linked immunosorbent assays (ELISAs) and indirect immuno uorescence (IIF) techniques for the detection of M2 anti-mitochondrial antibodies.
Introduction
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized by progressive in£ammatory obliteration of intrahepatic bile ducts, leading to ¢brosis, liver cell damage and ultimately liver failure. 1 IgG anti-mitochondrial antibodies (AMA) in high titres are detected by indirect immuno£uorescence (IIF) in rodent liver^kidney^stomach substrate (triple block sections) in 490% of patients with PBC, and the M2 pattern is highly speci¢c for PBC. 2, 3 However, low titres of other non-M2 AMA are also detected by IIF in other diseases and in apparently healthy individuals and are of little diagnostic speci¢city. Subjective di¡erentiation of the M2 pattern requires considerable technical skill and experience.
Recombinant enzyme-linked immunosorbent assays (ELISAs) for M2 AMA are now available commercially but the precise diagnostic characteristics have yet to be de¢ned since the native M2 target autoantigen is a complex antigen and antibody responses are heterogeneous.
Four AMA types (anti-M2, -M4, -M8 and -M9) have been detected in serum from patients with PBC using di¡erent mitochondrial subfractions. 4 Most laboratories use IIF on rat liver and kidney cells or human epithelial (HEp-2) cells for anti-M2 screening. Although anti-M2 is reported in 96% of patients with clinically and histologically de¢ned PBC using experimental ELISAs against puri¢ed M2 mitochondrial subfractions, 5 only 85% may show typical M2 patterns on rodent IIF. 6 Between 4% and 10% of patients with clinical and histological ¢ndings of PBC lack detectable AMA by standard IIF. 7 Little comparative work has been published, but most specimens that are PBC-negative on IIF may remain negative in ELISA. 8 We examined whether or not the two ELISAs that were commercially available at the time of the study were speci¢c for PBC compared with IIF techniques, and examined the predictive values of rodent tissue screening versus HEp-2 screening followed by con¢rmation of speci¢city by ELISA.
Methods
Serum samples from 190 individuals (137 women, 53 men), including 55 controls, were tested for AMA by each assay method using only a sample number to identify each specimen. The diagnoses were: biopsyproven PBC (nˆ38), rheumatoid arthritis (nˆ24), systemic lupus erythematosus (nˆ54), systemic sclerosis (nˆ9), SjÎgren's syndrome/sicca syndrome (nˆ10); the control population were normal blood donors (nˆ55). None of the non-PBC patients or control cohorts had any known liver disease (all had normal liver transaminases), symptoms of PBC or had had a liver biopsy. Ethical permission was obtained from the North She¤eld Research Ethics Committee.
The operator was unaware of the diagnosis or source of the sample at the time of investigation. All IIF results were read by two independent observers, and no discrepancies were noted.
Rodent liver^kidney^stomach tissue substrate (Biodiagnostics) and the human epithelial cell line HEp-2000 1 , a modi¢ed version of the standard Hep-2 cell line (Immuno Concepts, USA) were used for the IIF. ELISA A (Varelisa, Germany) and ELISA B (Cogent, USA) were performed on the same specimens.
Patients' serum samples were screened by IIF at a dilution of 1:20 in phosphate-bu¡ered saline (PBS) for 30 min, washed in PBS and labelled with £uorescein isothiocyanate (FITC)-labelled swine anti-human Ig (Nordic Immunology, The Netherlands). IIF was read on a Leitz Wetzlar Orthoplan £uorescence microscope using a 450^500-nm ¢lter. Positive and negative controls were included in each run. The presence or absence of M2 or non-M2 AMA staining was determined using published diagnostic criteria. 9 HEp-2000 cells were labelled with serum diluted 1:40 in PBS as above but using goat anti-human IgGF ITC conjugate (Incstar, USA). Dilutions of conjugate and serum were optimized using chequer-board techniques. ELISA A for M2 AMA is a solid-phase immunosorbent assay using recombinant substrate; the reference curve was constructed from six antibody standards. ELISA B for M2 AMA is a solid-phase immunosorbent assay using puri¢ed substrate; the standard curve comprised four antibody standards. Both ELISAs were performed according to the manufacturer's instructions. Photometric (optical density) quantitation was made using a microtitre plate reader (Sorin Biomedica ETI system) at 450 nm. Positive and negative controls were performed on each run. Each sample was assayed in duplicate and reported in arbitrary ELISA units. It should be noted that ELISA A units are not equivalent to ELISA B units. No international reference preparation is available for calibration of these assays.
Statistical analysis
Statistical associations between methods and within methods were calculated using Pearson's correlation test (r). Sensitivity, speci¢city and positive and negative predictive values (PPV, NPV) were calculated according to standard algorithms. 10 Table 1 shows the percentage of specimens found to be positive for M2 AMA for each of the four methods, and Table 2 summarizes the sensitivity, speci¢city, PPV and NPV for each method. The results demonstrate 
Results
Controls (nˆ55) 0 (0) 0 (0) 0 (0) 5 (9) IIFˆindirect immuno uorescence; ELISAˆenzyme-linked immunosorbent assay; HEpˆhuman epithelial cells.
that ELISA and IIF can have very di¡erent diagnostic characteristics. ELISA B had lower predictive values for PBC and produced positivity in other diseases without obvious clinical evidence of PBC, in the absence of con¢rmatory IIF positivity. A strong correlation existed between the two IIF methods (Pearson, rˆ0.854). Both IIF methods were highly speci¢c (99%) and moderately sensitive (74%) ( Table 2 ). The speci¢city of both IIF methods was slightly better than that of the best ELISA although the ELISAs were marginally more sensitive within the PBC cohort. ELISA B produced a signi¢cant number of positive patients in each cohort that were not detected by ELISA A (Table 1 ). These results indicate that ELISA B has a poorer PPV and speci¢city. Three PBC patients were AMA-positive on rat tissue and ELISA A but not on HEp-2000, and three PBC patients showed AMAtype cytoplasmic HEp-2000 staining without any other con¢rmatory tests (Table 3) .
Few ELISA A positives were not con¢rmed by IIF, whereas many ELISA B positives were not con¢rmed by IIF.
Discussion
We have shown that both IIF methods are more speci¢c than ELISA for the diagnosis of PBC. However, the sensitivities of the ELISAs are slightly greater than those of the IIF methods. This suggests that IIF on rodent or HEp-2000 tissue remains the method of choice for screening serum but that an appropriately validated ELISA, such as ELISA A, may be useful in con¢rming the speci¢city of the AMA in cases of doubt, or when HEp-2 cells are used as a screening technique. IIF methods require signi¢cant experience in interpreting subjective patterns but ELISAs produce a clear quantitative and qualitative result, provided the predictive value of the assay has been properly validated.
A strong correlation (rˆ0¢854) exists between the results obtained by the two IIF methods currently used in this department [rodent tissue (kidneyŝ tomach^liver) and HEp-2000 slides], con¢rming that HEp-2 cells are a suitably sensitive substrate for the detection of M2 AMA, although a second technique (rodent IIF or ELISA) must be used to distinguish M2 AMA from other patterns. Although a correlation exists between the two ELISAs (rˆ0¢7369), ELISA B produced too many positive results in the cohorts of patients and controls without evidence of liver disease to be useful clinically. The strong correlation between the rodent IIF and ELISA A (rˆ0¢9134) is not seen with ELISA B (rˆ0¢599).
In total, 22 non-PBC patients and controls showed a discrepancy between ELISA B and the three other assays (see Table 3 ), with 5 (9%) of the control population being positive in ELISA B but negative by all the other methods (see Table 1 ). The poor predictive value of ELISA B does not appear to be due to an inappropriately low cut-o¡. Raising the threshold eliminates many`true' positive results in PBC patients and actually reduces negative predictive values and sensitivities. Another possibility might be that the antigen used to coat the wells of the ELISA plate included impurities. ELISA A utiliz es a recombinant PDH that is stated to contain immunoreactive epitopes, whereas ELISA B utilizes a protein puri¢ed in-house. The manufacturers have not divulged information regarding the precise nature of the antigen used to coat the wells of the microtitre plate. Although it is often the case that recombinant antigens are less likely to contain all the relevant epitopes than native puri¢ed proteins, studies by Leung et al. 11 suggest that recombinant protein antigens may be more speci¢c than puri¢ed M2 antigens, perhaps as a result of less contamination with other non-E2 subfraction mitochondrial antigens.
Occasional discrepancies between the four methods were found: for example, 2% of the PBC population produced positive AMA results by IIF but negative anti-M2 results by the ELISAs. This suggests that other autoantibody speci¢cities apart from the pyruvate dehydrogenase complex (PDC-E2) may be present in some patients (e.g. protein X). The alternative autoantibody speci¢cities may not be detected by the ELISAs due to the type of antigen used to coat the wells. Approximately 10% of specimens from PBC patients contain autoantibodies towards the branched-chain oxoacid dehydrogenase complex (BCOADC-E2) but not towards PDC-E2. 12 Such patients would be missed by ELISA diagnostic assays, which are usually coated with PDC-E2 substrate and have a low sensitivity to antibodies against E2 subunits of the BCOADC-E2. It is possible that such discrepancies could be overcome by constructing a hybrid molecule that contains the immunodominant epitopes of both PDC-E2 and BCOADC-E2; 11 this might improve the clinical utility of the assays. Alternatively, the antigens used in the ELISAs may represent alternative subtypes of AMA that are not present in the recombinant or puri¢ed ELISA protein substrate (e.g. anti-M4, anti-M9). It is very di¤cult to di¡erentiate AMA subtypes by IIF methods because the characteristic M2 staining of renal distal tubules and gastric parietal cells on the rodent kidney and stomach are indistinguishable from the M4 pattern. Newly available ELISA kits for the detection of M4 antibodies using wells coated with sulphite oxidase may identify the M4 patients from the M2 patients, 13 but these assays must also be appropriately validated in well-de¢ned clinical cohorts.
This study highlights the need for critical evaluation of all new commercial methods of autoantibody detection as part of good laboratory practice.
